Laprosep Komb (Timolol Maleate, Latanoprost)

Timolol reduces the production of aqueous humor by blocking β‑adrenergic receptors, while Latanoprost increases the outflow of fluid through the uveoscleral pathway as a prostaglandin analog. Their combined action provides a greater reduction in eye pressure than either agent alone.

The dosing regimen for Laprosep Komb is determined by the prescribing ophthalmologist based on the patient’s condition, response, and tolerance. Typically, one drop is instilled in the affected eye(s) once daily, but the exact schedule should follow the prescriber’s instructions.

Safety data for Laprosep Komb in pregnancy and lactation are limited. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made in consultation with a healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Compared with monotherapy, the combination of Timolol and Latanoprost offers dual mechanisms—decreased fluid production and increased outflow—resulting in a more pronounced and consistent intra‑ocular pressure reduction, often allowing patients to avoid multiple separate drops.

Laprosep Komb should be stored at room temperature, below 25 °C, in the original container, protected from light and moisture. Keep the bottle tightly closed when not in use and discard any solution that appears discolored or contaminated.

The product is supplied as sterile eye drops. The patient should wash hands, tilt the head back, pull down the lower eyelid, and place a single drop into the conjunctival sac. Close the eye gently and avoid blinking excessively for a few seconds.

Serious risks include severe allergic reactions, sudden increase in intra‑ocular pressure, significant vision loss, systemic bradycardia or hypotension, and respiratory difficulties in patients with asthma or COPD. Any such symptoms require immediate medical attention.

Patients with known hypersensitivity to Timolol, Latanoprost, or any excipients, those with severe bronchial asthma, chronic obstructive pulmonary disease, sinus bradycardia, second‑ or third‑degree heart block, or uncontrolled heart failure should avoid using Laprosep Komb unless advised otherwise by a physician.